Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

about

Casting the net broader to confirm our imaginations: the long road to treating wasting disorders.An analysis of the types of recently published research in the field of cachexia.

P2860

Q47132964-C312C977-505D-48F4-BA48-B763BEA99334 Q47568983-4794BDAE-FAD3-4FD2-814D-0C0E90DF4826

P2860

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

Item

http://www.wikidata.org/entity/Q42770577

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

@en

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

@nl

type

Item

label

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

@en

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

@nl

prefLabel

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

@en

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

@nl

P1476

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

@en

P2093

Jochen Springer

http://www.w3.org/2001/XMLSchema#string

Junichi Ishida

http://www.w3.org/2001/XMLSchema#string

Masaaki Konishi

http://www.w3.org/2001/XMLSchema#string

Masakazu Saitoh

http://www.w3.org/2001/XMLSchema#string

P2860

Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment

Validating survivin as a cancer therapeutic target

Cancer cachexia: impact, mechanisms and emerging treatments

Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer.

Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults.

Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.

Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients.

Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer.

Butyrylcholinesterase as a prognostic marker: a review of the literature

The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1.

P304

235-236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCSM.12123

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27493877

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

4876072

http://www.w3.org/2001/XMLSchema#string

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

about

P2860

P2860

Growth differentiation factor-15 as a prognostic biomarker in cancer patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932